May 18, 2020 Viiv’s HIV success shows PrEP is not everything Gilead’s dominance of the HIV prevention market is set to be challenged by monotherapy.
August 22, 2019 Astra could use a voucher to cement roxadustat’s head start Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
